Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Series C brings in $150mm for gene therapy start-up Orchard Therapeutics
14 Aug 2018
Orchard Therapeutics Ltd. (autologous ex vivo gene therapies) brought in $150mm through an oversubscribed Series C round led by Deerfield Management, which was joined by new investors RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management, Ghost Tree Capital Group, and US- based health care focused funds, along with returning backers Temasek, Baillie Gifford, RTW Investments, Cowen Healthcare Investments, and Agent Capital. Cowen served as the placement agent.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?